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http://www.biomedcentral.com/1741-7015/11/263RESEARCH ARTICLE Open AccessMultimorbidity in bipolar disorder and
undertreatment of cardiovascular disease: a cross
sectional study
Daniel J Smith1*, Daniel Martin1, Gary McLean2, Julie Langan1, Bruce Guthrie3 and Stewart W Mercer2Abstract
Background: Individuals with serious mental disorders experience poor physical health, especially increased rates of
cardiometabolic morbidity and premature morbidity. Recent evidence suggests that individuals with schizophrenia
have numerous comorbid physical conditions that may be under-recorded and undertreated, but to date very few
studies have explored this issue for bipolar disorder.
Methods: We conducted a cross-sectional analysis of a dataset of 1,751,841 registered patients within 314 primary
care practices in Scotland, UK. Bipolar disorder was identified using Read Codes recorded within electronic medical
records. Data on 32 common chronic physical conditions were also assessed. Potential prescribing inequalities were
evaluated by analysing prescribing data for coronary heart disease (CHD) and hypertension.
Results: Compared to controls, individuals with bipolar disorder were significantly less likely to have no recorded
physical conditions (OR 0.59, 95% CI 0.54 to 0.63) and significantly more likely to have one physical condition
(OR 1.27, 95% CI 1.16 to 1.39), two physical conditions (OR 1.45, 95% CI 1.30 to 1.62) and three or more physical
conditions (OR 1.44, 95% CI 1.30 to 1.64). People with bipolar disorder also had higher rates of thyroid disorders,
chronic kidney disease, chronic pain, chronic obstructive airways disease and diabetes but, surprisingly, lower
recorded rates of hypertension and atrial fibrillation. People with bipolar disorder and comorbid CHD or
hypertension were significantly more likely to be prescribed no antihypertensive or cholesterol-lowering
medications compared to controls, and bipolar individuals with CHD or hypertension were significantly less likely to
be on two or more antihypertensive agents.
Conclusions: Individuals with bipolar disorder are similar to individuals with schizophrenia in having a wide range
of comorbid and multiple physical health conditions. They are also less likely than controls to have a primary-care
record of cardiovascular conditions such as hypertension and atrial fibrillation. Those with a recorded diagnosis of
CHD or hypertension were less likely to be treated with cardiovascular medications and were treated less
intensively. This study highlights the high physical healthcare needs of people with bipolar disorder, and provides
evidence for a systematic under-recognition and undertreatment of cardiovascular disease in this group.
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Individuals with bipolar disorder have a standardised
mortality rate (SMR) up to twice that of the general
population [1-9]. Although suicide is a major cause of
premature mortality in bipolar disorder, with a lifetime
risk of around 8% [10], most of the excess mortality as-
sociated with bipolar disorder and similar serious major
mental disorders is due to an increased prevalence of
cardiovascular, metabolic and endocrine conditions and
risky health behaviours [11,12]. Approximately 45% of
individuals with bipolar disorder are known to smoke,
compared with the population average of 20% [13]. It
is also estimated that approximately 10% of people
prescribed long-term antipsychotic medications will
develop type II diabetes (at least twice the rate in the
general population), and that 15% will develop hyper-
lipidaemia [14].
Despite higher rates of multiple medical comorbidities,
there is also evidence that individuals with major mental
illnesses receive less screening and fewer preventative
interventions [15] and that they find it more difficult
to implement lifestyle interventions aimed at modifying
cardiometabolic risk factors [16]. A large population-
based Danish study found that the recording of cardio-
vascular disease in individuals with bipolar disorder,
schizophrenia and schizoaffective disorder was incom-
plete, and management insufficiently intensive [17]. A
similar population-based cohort study in Sweden reported
that despite elevated mortality rates (approximately
double that of the general population) in bipolar disorder
for cerebrovascular disease, coronary heart disease and
acute myocardial infarction, hospital admission rates
for cardiovascular disorder were only slightly increased
compared to the general population. Taken together,
these findings indicate a need for better recognition and
treatment of physical health comorbidities in schizophrenia
and bipolar disorder.
In a previous study we identified that individuals with
schizophrenia in Scotland had significantly higher rates
of multiple medical comorbidities but lower than ex-
pected rates of cardiovascular diseases recorded within
primary care records [15]. Although it is reasonable to
expect similar findings for bipolar disorder, to date there
has been much less work carried out on the patterns
and severity of multimorbidity in bipolar disorder. A fuller
understanding of bipolar-specific patterns of comorbidity
will help with the development of new integrated treat-
ment approaches aimed at improving quality of life and
reducing premature mortality.
In this study we aimed not only to examine the nature
and extent of physical comorbidities in individuals with
bipolar disorder within primary care but also to assess
whether they experience inequitable prescribing for two
key conditions: coronary heart disease and hypertension.Methods
We used a dataset from the Primary Care Clinical
Informatics Unit at the University of Aberdeen, UK,
consisting of all 1,751,841 registered patients who were
alive and permanently registered with 314 general practices
on 31 March 2007. This representative sample covers ap-
proximately one-third of the Scottish population. Data on
the presence of 32 of the most common chronic physical
health conditions were extracted (listed in Appendix 1).
A more detailed explanation of how these conditions
were selected and defined is available elsewhere [18].
People were identified as having bipolar disorder based
on the recording at any point of any of the following pri-
mary care Read Codes (where % is noted this means ‘this
code and any below it in the code hierarchy’): E110%
Manic disorder, single episode/hypomanic psychosis;
E111% Recurrent manic episodes; E114% Bipolar affective -
now manic/manic depressive - now manic; E115% Manic-
depression - now depressed; E116% Manic bipolar affective
disorder; E117% Unspecified bipolar affect disorder; E11y;
Other manic-depressive psychosis; E11y0 Unspecified
manic-depressive psychosis; E11y1 Atypical manic disorder;
Eu30% Manic episode; Eu31 Bipolar affective disorder/
manic depressive illness/manic depressive psychosis; Eu323
Severe depressive + psychotic; and Eu333 Recurrent depres-
sion now severe + psychosis.
Deprivation status was measured using the Carstairs
deprivation score which is widely used in healthcare re-
search and is divided into quintiles to show differences
between bipolar and non-bipolar patients, as well as for
men and women with bipolar disorder [19]. Analysis was
restricted to those aged at least 18 years old. The sample
was divided into the following age groups for analysis: 18
to 24, 25 to 34, 35 to 44, 45 to 54, 55 to 64, 65 to 75, and
75 and over.
Differences between individuals with bipolar disorder
and all other individuals, as well as differences between
men and women with bipolar disorder, were calculated by
age, deprivation status, number of physical conditions,
cardiovascular risk factors (smoking, total serum choles-
terol and blood pressure) and prescribing data. We used t
tests to analyse differences between groups and one-way
analysis of variance (ANOVA) for differences across age
groups and deprivation quintiles. Age and gender specific
rates were generated by the seven age groups outlined
above. These age and gender standardised rates were then
used to calculate odds ratio (ORs) and 95% confidence in-
tervals (95% CIs) for those with bipolar disorder compared
with those without bipolar disorder for the prevalence of
all 32 physical conditions, as well as 0 physical disorders,
1 physical condition, 2 or more physical conditions and 3
or more physical conditions with results.
Standardised age and gender rates for risk factors and
prescribing measures were also generated. For risk factors
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and with hypertension with and without bipolar disorder
in terms of whether they were current smokers, ever
smokers, did not achieve target blood pressure (defined as
systolic blood pressure (SBP) ≥140 mmHg and diastolic
blood pressure (DBP) ≥90 mmHg if aged under 80 and
SBP ≥150 mmHg and DBP ≥90 mmHg if aged 80 and over),
or did not achieve total cholesterol ≤5 mmol/L (CHD
analysis only). Differences in prescribing between those
with and without bipolar disorder were also analysed by
comparing the percentage of patients on aspirin/clopidogrel
(for coronary heart disease only), a statin and antihyper-
tensive drugs (defined as any angiotensin-converting
enzyme inhibitor (ACEI) (all drugs in British National
Formulary (BNF) issue 51, chapter 2.5.5.1), any angioten-
sion II receptor blocker (ARB) (all drugs in BNF chapter
2.5.5.2), any beta blocker (all drugs in BNF chapter 2.4), any
calcium-channel blocker (all drugs in BNF chapter 2.6.2),
any alpha blocker (all drugs in BNF chapter 2.5.4), spirono-
lactone (selected drug from BNF chapter 2.2.3), any other
antihypertensive (all drugs in BNF chapter 2.5.1 or 2.5.2 or
2.5.3 or 2.5.4 not previously counted)). For all statistical
analyses, a P value less than 0.05 was considered to be
statistically significant. All analyses were performed in Stata
version 11.1 (Stata Corp., College Station, TX, USA).
The UK National Health Service (NHS) National
Research Ethics Service approved the anonymous use
of these data for research purposes.
Results and discussion
Age, gender and deprivation status, bipolar versus
non bipolar
We identified 2,582 people with a recorded bipolar read
code (0.2% of the entire sample) and 1,421,796 without a
bipolar read code (Table 1). Those with bipolar disorder
were less likely to be male (39.5% of the bipolar group
were male vs 49.1% of controls; P <0.001). Individuals with
bipolar disorder tended to be older (mean age 54.5 years vs
47.9 years for controls; P <0.001), with bipolar patients less
likely to be aged under 35 but more likely to be clustered in
the 45 to 75 age range. Individuals with bipolar disorder
were also less socially deprived (bipolar Carstairs score −0.31
vs. no bipolar −0.17; P <0.001) although differences between
quintiles were marginal.
Physical health comorbidity in people with bipolar
disorder versus controls
Physical health comorbidities were very common for people
with bipolar disorder, even after controlling for age and
gender. Compared to controls, the bipolar group were sig-
nificantly less likely to have 0 recorded physical conditions
(OR 0.59, 95% CI 0.54 to 0.63; P <0.001) and significantly
more likely to have 1 of the 32 most common physical con-
ditions (OR 1.27, 95% CI 1.16 to 1.39; P <0.001), 2 physicalcomorbidities (OR 1.45, 95% CI 1.30 to 1.62; P <0.001) and
3 or more physical comorbidities (OR 1.44, 95% CI 1.30
to 1.64; P <0.001) (see Table 2).
For each of the 32 individual physical conditions assessed,
prevalence was significantly higher for individuals with bi-
polar disorder for 15 conditions, lower for 2 conditions and
with no difference found for the remaining 15 conditions
(Table 2). Prevalence was highest for bipolar versus non-
bipolar for viral hepatitis (OR 5.69, 95% CI 3.22 to 10.01;
P <0.001), constipation (OR 3.37, 95% CI 2.93 to 3.88;
P <0.001) and Parkinson’s disease (OR 3.05, 95% CI
1.83 to 5.09; P <0.001) (see Figure 1).
People with bipolar disorder also had higher rates of
several important chronic health conditions relevant to
bipolar disorder for both unadjusted and adjusted results.
This included chronic kidney disease (7.3% in bipolar dis-
order vs 2.4% in controls; OR 2.42 P <0.001), thyroid disor-
ders (16.6% vs 5.0%; OR 2.39 P <0.001), chronic pain
(17.5% vs 8.8%; OR 1.88 P <0.001), chronic obstructive pul-
monary disease (COPD) (6.6% vs 3.7%; OR 1.39 P <0.001),
and diabetes (8.4% vs 5.2%; OR 1.31 P <0.001).
The most commonly diagnosed condition for individ-
uals with bipolar was hypertension (17.9%), but this was
significantly lower than in the general population after
controlling for age and gender, (OR 0.82, 95% CI 0.73
to 0.82; P <0.001). The only other physical condition in
which the prevalence for bipolar patients was significantly
lower following standardisation was atrial fibrillation
(OR 0.68, 95% CI 0.45 to 0.94; P = 0.02).
Cardiovascular risk factors and prescribing of
cardiovascular medications
Table 3 shows differences in risk factors and prescribing
levels for bipolar disorder and controls with coronary
heart disease (CHD) and/or hypertension. Although the
rate of ever smoking was very similar (67.6% for bipolar
vs 63.3% for controls; P = 0.95), bipolar patients with CHD
were more likely to be current smokers than controls
(32% vs 20.6%; OR 1.55, 95% CI 1.11 to 2.17; P = 0.01). No
difference was found for the achievement of cholesterol
and blood pressure targets between individuals with bipolar
disorder and controls. Bipolar patients with CHD were less
likely to be on a statin (70.0% of bipolar vs 74.4% controls;
OR 0.69, 95% CI 0.50 to 0.96; P = 0.02), more likely not to
be on an antihypertensive (29.4% vs 15.8%; OR 2.08,
95% CI 1.49 to 2.91; P <0.001) and less likely to be on
two or more antihypertensive medications (32.9% vs 52.7%;
OR 0.46, 95% CI 0.33 to 0.63; P <0.001). There was no
difference found for aspirin or clopidogrel prescribing.
Bipolar patients with hypertension were more likely to
be current smokers (27.9% vs 17.1%; OR 1.87, 95% CI 1.53
to 2.39; P <0.001) and more likely to have ‘ever smoked’
(54.5% vs 48.9%; OR 1.25, 95% CI 1.04 to 1.50; P <0.001).
They were less likely to be on a statin (36.7% vs 41.5%; OR
Table 1 Age, gender and deprivation status
Variable Bipolar, n (%) Not bipolar, n (%) Difference (95% CI) (P value)
Total 2,582 (0.2) 1,421,796 (99.8)
Gender (% male) 1,021 (39.5) 698,408 (49.1) −9.6 (−7.6 to −11.5) (P <0.001)
Age, mean (SD) 54.5 (15.3) 47.9 (18.2) 6.5 (5.7 to 7.2) (P <0.001)
Deprivation, mean (SD) −0.31 (3.3) −0.17 (3.3) 0.14 (−0.8 to 0.1) (P = 0.03)
Age group:
18 to 24 45 (1.7) 151,648 (10.7) −9.0 (−7.8 to −10.1) (P <0.001)
25 to 34 217 (8.4) 229,179 (16.1) −7.7 (−6.3 to −9.1) (P <0.001)
35 to 44 445 (17.2) 278,548 (19.6) −2.4 (−0.1 to −3.9) (P = 0.01)
45 to 54 626 (24.2) 253,168 (17.8) 6.4 (5.0 to 7.9) (P <0.001)
55 to 64 547 (21.2) 218,786 (15.4) 5.8 (4.4 to 7.1) (P <0.001)
65 to 74 410 (15.9) 154,870 (10.9) 5.0 (3.8 to 6.2) (P <0.001)
75 and over 292 (11.3) 135,597 (9.5) 1.8 (0.1 to 2.9) (P <0.001)
Deprivation quintile:
1 (least deprived) 513 (19.9) 271,516 (19.1) 0.8 (−0.2 to 1.4) (P = 0.32)
2 570 (22.1) 303,584 (21.4) 0.7 (−0.1 to 1.2) (P = 0.37)
3 581 (22.5) 321,666 (22.6) −0.1 (−1.4 to 0.8) (P = 0.88)
4 514 (19.8) 270,870 (19.1) 0.8 (−0.2 to 1.6) (P = 0.23)
5 (most deprived) 404 (15.7) 254,160 (17.9) 2.2 (0.8 to 3.7) (P <0.001)
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on an antihypertensive agent (21.8% vs 13.9%; OR 1.70
95% CI 1.36 to 2.12; P <0.001) and less likely to be on two
or more antihypertensive medications (37.8% vs 53.7%;
OR 0.53, 95% CI 0.44 to 0.67; P <0.001).
Gender differences within the bipolar group
We also assessed whether there might be differences be-
tween men and women with bipolar disorder in terms of
the number of recorded physical health comorbidities, as
well as age and deprivation status (Table 4). On average,
women were older than men (55.8 to 52.4; P <0.001).
Physical comorbidity was high in all bipolar patients, with
two-thirds of both men and women having at least one
recorded comorbid physical condition (Table 4). Women
with bipolar disorder were significantly more likely to have
three or more physical conditions than men (25.0% versus
17.0%; P <0.001).
Discussion
General findings
Our findings highlight that individuals with bipolar disorder
have excess physical health comorbidities compared to
the general population. Similar to our recent findings
for schizophrenia [15], the majority of individuals with
bipolar disorder (63.9%) had at least one chronic phys-
ical health comorbidity. Compared to patients without
bipolar disorder, individuals with bipolar disorder were
more likely to have a primary care record of both sin-
gle and multiple physical health problems, even aftertaking into account age, gender and deprivation status.
In general, our findings for bipolar disorder are similar
to previous findings for schizophrenia, that is, for both
conditions there appear to be high rates of multiple co-
morbidities and a systematic under-recording of car-
diovascular conditions [15]. However, in the current
paper we have extended this work by also identifying
that individuals with bipolar disorder and a primary
care record of coronary heart disease or hypertension
tend to experience much less intensive prescribing for
these conditions.
Specific conditions
The three conditions with the highest prevalence within
the bipolar group were viral hepatitis, constipation and
Parkinson’s disease (which includes Parkinsonism). There
were also high rates of diabetes, chronic pain and COPD.
Perhaps at least partly as a consequence of known
treatment side effects (for example, lithium therapy),
thyroid disease and chronic kidney disease both also
had higher prevalence, again after age/sex adjustment,
compared to controls.
The relatively high rates of viral hepatitis, constipation
and Parkinson’s disease may have a number of explanations.
There are high rates of drug abuse in bipolar disorder
[20] and within Scotland there is a national programme
of testing for blood borne viruses in those diagnosed
with drug dependence. This may explain the relatively
high rates of viral hepatitis recorded in the bipolar
group. Features of Parkinson’s disease can be a direct
Table 2 Prevalence and odds ratios for physical health comorbidity, standardised by age and gender
Variable Bipolar, n (%) Not bipolar, n (%) Odds ratio (95% CI) (P value)
No physical condition 929 (36.0) 799,179 (56.2) 0.59 (0.54 to 0.63) (P <0.001)
One physical condition 662 (25.6) 292,651 (20.6) 1.27 (1.16 to 1.39) (P <0.001)
Two physical comorbidities 427 (16.5) 149,297 (10.5) 1.45 (1.30 to 1.62) (P <0.001)
Three or more physical comorbidities 564 (21.8) 180,669 (12.7) 1.44 (1.30 to 1.64) (P <0.001)
Individual conditions:
Viral hepatitis 10 (0.4) 1,165 (0.1) 5.69 (3.22 to 10.01) (P <0.001)
Constipation 249 (9.4) 36,167 (2.5) 3.37 (2.93 to 3.88) (P <0.001)
Parkinson’s disease/Parkinsonism 19 (0.7) 2,722 (0.2) 3.05 (1.83 to 5.09) (P <0.001)
Chronic kidney disease 189 (7.3) 33,377 (2.4) 2.42 (2.04 to 2.86) (P <0.001)
Thyroid disorders 376 (14.6) 71,567 (5.0) 2.39 (2.11 to 2.70) (P <0.001)
Inflammatory bowel disease 27 (1.1) 9,724 (0.7) 1.99 (1.42 to 2.78) (P <0.001)
Epilepsy 47 (1.8) 12,337 (0.9) 1.98 (1.46 to 2.66) (P <0.001)
Pain 451 (17.5) 125,680 (8.8) 1.88 (1.69 to 2.09) (P <0.001)
Prostate disease 46 (1.8) 15,187 (1.1) 1.71 (1.28 to 2.29) (P <0.001)
Dyspepsia 237 (9.2) 78,967 (5.6) 1.63 (1.42 to 1.87) (P <0.001)
Blindness or low vision 30 (1.2) 8,348 (0.6) 1.58 (1.06 to 2.37) (P = 0.02)
Multiple sclerosis 16 (0.6) 3,831 (0.3) 1.58 (0.87 to 2.86) (P = 0.12)
Psoriasis or eczema 31 (1.2) 10,338 (0.7) 1.44 (0.98 to 2.10) (P = 0.06)
Chronic obstructive pulmonary disease 169 (6.6) 52,938 (3.7) 1.39 (1.17 to 1.65) (P <0.001)
Irritable bowel syndrome 148 (5.7) 51,989 (3.7) 1.37 (1.14 to 1.64) (P <0.001)
Diabetes 218 (8.4) 74,613 (5.3) 1.31 (1.13 to 1.53) (P <0.001)
Liver disease 6 (0.2) 2,608 (0.2) 1.26 (0.56 to 2.82) (P = 0.56)
Cancer 115 (4.5) 43,549 (3.1) 1.23 (1.00 to 1.54) (P = 0.04)
Hearing loss 134 (5.2) 54,600 (3.8) 1.18 (0.98 to 1.43) (P = 0.07)
Peripheral vascular disease 59 (2.3) 23,181 (1.6) 1.18 (0.93 to 1.56) (P = 0.22)
Asthma 179 (6.9) 83,809 (5.9) 1.16 (0.99 to 1.35) (P = 0.06)
Heart failure 47 (1.8) 18,852 (1.3) 1.11 (0.80 to 1.53) (P = 0.51)
Diverticular disease 89 (3.5) 33,724 (2.4) 1.11 (0.87 to 1.41) (P = 0.38)
Stroke and transient ischaemic attack 89 (3.5) 36,456 (2.6) 1.05 (0.84 to 1.34) (P = 0.63)
Inflammatory arthritis and related conditions 119 (4.6) 57,889 (4.1) 0.95 (0.78 to 1.17) (P = 0.67)
Coronary heart disease 170 (6.6) 81,297 (5.7) 0.94 (0.79 to 1.12) (P = 0.51)
Chronic sinusitis 17 (0.7) 9,148 (0.6) 0.90 (0.54 to 1.49) (P = 0.69)
Migraine 18 (0.7) 9,233 (0.7) 0.89 (0.54 to 1.49) (P = 0.67)
Hypertension 462 (17.9) 233,852 (16.5) 0.82 (0.73 to 0.92) (P <0.001)
Glaucoma 28 (1.1) 15,891 (1.2) 0.82 (0.55 to 1.24) (P = 0.36)
Atrial fibrillation 39 (1.4) 23,937 (1.7) 0.68 (0.45 to 0.94) (P = 0.02)
Bronchiectasis 5 (0.2) 2,809 (0.2) 0.78 (0.29 to 2.08) (P = 0.62)
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clear mechanism for increased rates of constipation
within bipolar disorder, psychological symptoms including
those experienced as part of significant mood disorder
are related to symptoms of irritable bowel syndrome in-
cluding constipation [21,22]. Furthermore, constipation is
an under-recognised side effect of antipsychotic medicationthat can significantly impact on quality of life, experienced
by 20% to 30% of all patients prescribed such drugs [23].
Recording of cardiovascular comorbidity
Rates of coronary heart disease, heart failure, stroke, and
transient ischaemic attack (TIA) and peripheral vascular
disease were not significantly elevated in the bipolar
Figure 1 Odds ratios for individual conditions.
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tic conditions including smoking and diabetes mellitus
were found to be very significantly elevated in patients
with bipolar disorder. Furthermore, individuals from
the bipolar group displayed lower recorded rates of
hypertension and atrial fibrillation compared to those
without bipolar disorder. These findings might be un-
expected given existing knowledge on physical comor-
bidity in bipolar disorder [11,12,15,16], but, as noted
above, recent reports have highlighted that physical
comorbidity in major mental illness is often underdiag-
nosed and undertreated [15-17,24].
There is strong evidence of under-recognition of car-
diovascular disease in people with major mental illness.
A recent Swedish national cohort study found that in-
dividuals with schizophrenia were more likely to die
prematurely than the general population (15 years earlier
for men and 12 years earlier for women) and the leading
causes of death were cardiovascular disease and cancer.
However, rates of recording of cardiovascular disease
and cancer were only slightly increased in people with
schizophrenia, even though these individuals had more
healthcare system contacts, suggesting that cardiovas-
cular disease and cancer are significantly underdiag-
nosed and/or under-recorded in this population [24].
Furthermore, using a similar approach to the one used
in this study, we have identified an under-recording of
cardiovascular illness in individuals with schizophrenia
compared to expectations [15].
Our findings suggest a strong likelihood of under-
recording of cardiovascular disease in bipolar disorder.There are a number of possible reasons for this health
inequality. People with bipolar disorder may be less likely
to seek help from their general practitioner (GP) with
symptoms of cardiovascular disease because of low
awareness of cardiovascular risk factors and associated
symptoms [25]. This could be due to mental state abnor-
malities, social isolation and in some cases low levels of
education. Cardiovascular risk estimation tools such as
Framingham, ASSIGN and QRISK have not been vali-
dated in individuals with major mental illness [26] and
may underestimate cardiovascular risk in bipolar patients,
who are typically younger, smoke more and have higher
blood pressure than the population traditionally used to
generate the cardiovascular risk. This too may compound
problems with under-recognition and undertreatment.
People with bipolar disorder may also be prone to less
regular attendance at clinics because of depressive and
manic or hypomanic episodes [27].
Prescribing of cardiovascular medications
A recent meta-analysis of prescribing data for patients
with and without major mental illness found that individ-
uals with a history of major mental illness had significantly
lower prescription rates for cardiovascular medications
[16]. Our findings indicate a similar prescribing disparity
for both cholesterol lowering and antihypertensive medi-
cations. People with bipolar disorder and both coronary
heart disease and hypertension had lower rates of statin
prescription, as well as less intensive treatment with an-
tihypertensive drugs. Although there was no evidence of
different rates of poor blood pressure control and high
Table 3 Differences in risk factors and prescribing between bipolar and controls for coronary heart disease (CHD) and
hypertension patients standardised by age and gender
Patients Bipolar Controls Odds ratio (95% CI)
CHD patients: n = 170 n = 80,985
Current smokers, % 32.3 20.6 1.55 (1.11 to 2.17) P = 0.01
Ever smokers, % 67.6 63.3 1.00 (0.73 to 1.37) P = 0.95
n = 147 n = 73,508
Total cholesterol >5, % 18.6 18.3 1.02 (0.73 to 1.37) P = 0.95
n = 170 n = 80,863
Blood pressure not controlled, %* 1.1 2.3 0.24 (0.03 to 1.74) P = 0.16
Prescribed drugs n = 170 n = 81,297
Aspirin or clopidogrel, % 69.3 73.6 0.81 (0.58 to 1.12) P = 0.20
Statin, % 70.0 74.9 0.69 (0.50 to 0.96) P = 0.02
No antihypertensive, % 29.4 15.8 2.08 (1.49 to 2.91) P <0.001
One antihypertensive, % 37.6 31.3 1.29 (0.94 to 1.76) P = 0.10
Two or more antihypertensives, % 32.9 52.7 0.46 (0.33 to 0.63) P <0.001
Hypertension patients: n = 462 n = 232,986
Current smokers, % 27.9 17.1 1.87 (1.53 to 2.39) P <0.001
Ever smokers, % 54.5 48.9 1.25 (1.04 to 1.50) P <0.001
n = 462 n = 232.915
Blood pressure not controlled, %* 6.5 6.6 0.94 (0.64 to 1.37) P = 0.77
Prescribed drugs n = 462 n = 233,852
Statin, % 36.7 41.5 0.82 (0.68 to 0.98) P = 0.04
No antihypertensive, % 21.8 13.9 1.70 (1.36 to 2.12) P <0.001
One antihypertensive, % 39.8 32.3 1.38 (1.15 to 1.67) P <0.001
Two or more antihypertensives, % 37.8 53.7 0.53 (0.44 to 0.68) P <0.001
Prescribing based on previous 84 days. Antihypertensives include any angiotensin-converting enzyme inhibitor (ACEI), angiotension II receptor blocker (ARB), beta
blocker, calcium channel blocker, thiazide, alpha blocker, spironolactone or other antihypertensive.
*Blood pressure not controlled calculated as systolic blood pressure (SBP) ≥140 plus diastolic blood pressure (DBP) ≥90 if aged under 80, and SBP ≥150 plus
DBP ≥90 if aged 80 and over.
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with CHD/hypertension comorbidity versus non-bipolar
patients with CHD/hypertension, it is important to note
that for people with CHD statins are recommended for
all patients irrespective of pretreatment cholesterol level,
so lack of prescription is indicative of a missed opportun-
ity to deliver an evidence-based intervention. For people
with hypertension, lower treatment intensity in the face
of similar blood pressure or cholesterol control is more
ambiguous. However, it is not possible to fully explore the
relationship between treatment and outcome in cross-
sectional data, particularly given the substantial prema-
ture cardiovascular mortality in bipolar disorder [1,12],
consistent with people who were undertreated and
with poor intermediate outcome control not surviving
to be analysed in this kind of cross-sectional analysis.
Our study cannot fully examine this issue, but highlights
the importance of assessing treatment, intermediate
outcome, and cardiovascular events and mortality within
longitudinal research.Although there are no universally accepted explanations
for differences in prescribing for those with major mental
illness, a number of possibilities exist. Mental health
professionals may fail to appropriately diagnose phys-
ical health problems in their patients [28,29], they may
carry out incomplete physical examinations [30] and a
proportion may not feel confident with prescribing physical
health (non-psychotropic) medications [16]. Despite this,
most pharmacological treatments for cardiovascular illness
take place in primary care. General practitioners who do
not feel confident in managing complex and severe mental
illness may be less likely to follow-up patients with major
mental illness and comorbid physical health problems [31].
There are, however, conflicting reports within the literature
that suggest that a higher frequency of healthcare visits
in the context of mental illness may result in increases
in guideline-recommended care for comorbid physical
conditions [32]. Moreover, health care professionals
working with individuals with major mental illness may be
cautious when prescribing for this group due to concerns
Table 4 Differences between men and women with bipolar disorder
Variable Men, n (%) Women, n (%) Difference 95% CI (P value)
Total 1,021 (39.5) 1,561 (60.5)
Age, mean (SD) 52.4 (15.1) 55.8 (15.2) −3.4 (2.2 to 4.5) (P <0.001)
Deprivation, mean (SD) −0.40 (3.2) −0.25 (3.4) 0.15 (−0.3 to 1.2) (P = 0.27)
Age group:
18 to 24 20 (2.0) 25 (1.6) 0.4 (−0.3 to 0.7) (P = 0.49)
25 to 34 111 (10.9) 106 (6.8) 4.1 (1.8 to 6.2) (P <0.001)
35 to 44 195 (19.1) 250 (16.0) 3.1 (1.1 to 6.1) (P = 0.4)
45 to 54 253 (24.8) 373 (23.9) 0.9 (−0.4 to 2.4) (P = 0.60)
55 to 64 214 (21.0) 333 (21.3) −0.3 (−0.2 to 3.5) (P = 0.82)
65 to 74 136 (13.3) 274 (17.6) 4.3 (1.3 to 7.1) (P <0.001)
75 and over 92 (9.0) 200 (12.8) 3.8 (1.3 to 6.9) (P <0.001)
Deprivation quintile
1 (least deprived) 207 (20.3) 306 (19.6) 0.7 (−0.3 to 2.4) (P = 0.67)
2 228 (22.3) 342 (21.9) 0.4 (−0.3 to 2.8) (P = 0.80)
3 230 (22.5) 351 (22.5) 0.0 (−3.4 to 3.3) (P = 0.98)
4 213 (20.9) 301 (19.3) 1.6 (−0.4 to 2.3) (P = 0.33)
5 (most deprived) 143 (14.0) 261 (16.7) −2.7 (−1.1 to 5.5) (P = 0.06)
Multimorbidity:
No physical comorbidity 430 (42.1) 499 (32.0) 10.1 (6.3 to 13.9) (P <0.001)
One physical comorbidity 399 (25.8) 263 (25.6) 0.2 (−3.2 to −3.1) (P = 0.91)
Two physical comorbidities 154 (15.1) 273 (17.4) −2.3 (−0.1 to 5.4) (P = 0.10)
Three physical comorbidities 174 (17.0) 390 (25.0) −8.0 (4.6 to 11.1) (P <0.001)
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such as beta blockers, may be dangerous in overdose
[16,33]. As noted above, it is also possible that con-
cordance with healthcare provision, including attend-
ance at GP and outpatient clinics, may be reduced in
those with major mental illness [16]. Our results in re-
lation to prescribing are potentially of concern because
the adherence to cardiovascular medication in individ-
uals with major mental illness may be even lower than
the prescribing data suggests.
Strengths and limitations
Strengths of this study include a very large sample
(almost 1.8 million individuals) which is representative of
the Scottish population and which has been selected from
314 primary care practices. It is worth noting that we have
used routine data from primary care in this study rather
conducting an epidemiological study. We believe that this
large sample of ‘real world’ patients has some important
advantages over an epidemiological study which, although
more systematic with regards to diagnosis, will inevit-
ably be smaller and almost certainly less representative
because it will depend upon the referral of patients or
volunteering patients.Our use of Read Codes to identify both the index con-
dition (bipolar disorder) and multiple medical comorbid-
ities is potentially imperfect but represents the trade off
between diagnostic accuracy and real-world representa-
tiveness and utility that is implicit in choosing between
epidemiological studies and routine data studies. Clearly
some estimates for some conditions may have been
prone to bias. For example, as noted above, higher re-
corded rates of viral hepatitis and thyroid disease for
bipolar patients may be related to more frequent blood
monitoring within this group.
The rate of a recorded diagnosis of bipolar disorder of
0.2% is lower than might be expected, with most esti-
mates of the prevalence of bipolar disorder being around
1% [34]. This likely reflects both underdiagnosis com-
pared to epidemiological estimates, and under-recording
reflecting the considerable debate and variation in the
definitions and prevalence of the condition. However,
this was not an epidemiological study but rather used
routine clinical data on a very large number of participants.
Our sample therefore represents the more severe end of
the bipolar spectrum and we can be reasonably confident
that most individuals recorded as having bipolar disorder
did indeed have the condition.
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are known to secondary care services but are not re-
corded within primary care and that a small additional
proportion may not be in contact with either primary orTable 5 Definitions of 32 physical health conditions assessed
Condition Variable name
Coronary heart disease CHD
Chronic kidney disease CKD
Asthma (active) Asthma
Atrial fibrillation Atrial fibrillation
Epilepsy Epilepsy
New cancer in the last 5 years Cancer
Thyrotoxicosis/thyroid disorders
(includes hypothyroidism)
Thyroid Disorders
Diabetes Diabetes
Parkinson’s disease Parkinson’s diseas
Multiple sclerosis Multiple sclerosis
Stroke or transient ischaemic attack Stroke or TIA
Blindness and low vision Blindness
Glaucoma Glaucoma
Hearing loss Hearing loss
Hypertension Hypertension
Heart failure Heart failure
Peripheral vascular diseases PVD
Chronic sinusitis Sinusitis
Bronchitis, emphysema and other chronic obstructive
pulmonary diseases
COPD
Bronchiectasis Bronchiectasis
Crohn’s disease and ulcerative colitis Inflammatory
bowel disease
Diverticular disease of intestine Diverticular diseas
Rheumatoid arthritis, other inflammatory polyarthropathies
and systematic connective tissue disorders
Inflammatory arthr
Hyperplasia of prostate and prostate disorders Prostate disease
Psoriasis or eczema Psoriasis/eczema
Viral hepatitis Viral hepatitis
Irritable bowel syndrome Irritable bowel
syndrome
Cirrhosis/chronic liver disease/alcoholic liver disease Chronic liver dise
Migraine Migraine
Dyspepsia Dyspepsia
Constipation Constipation
Pain Pain
BNF British National Formulary, NSAID non-steroidal anti-inflammatory drug, POM psecondary care. Further, these are routine data from 314
primary care practices and there may be some variability
of diagnostic coding for major mental illnesses across
these practices.Variable definition
Read code ever recorded
Read code ever recorded
Read code ever recorded AND any prescription in last year
Read code ever recorded
Read code ever recorded AND epilepsy prescription in last year
Read code first recorded in last 5 years (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded
e Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
e Read code ever recorded (Relevant Read Code recorded)
itis Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (M11% and M12%) AND ≥4 prescriptions
in last year (BNF 13.4, excluding hydrocortisone, and BNF 13.5)
Read code ever recorded (Relevant Read Code recorded)
Read code ever recorded (Relevant Read Code recorded) OR
≥4 antispasmodic prescription in last year (POM only, exclude
kolanticon, alverine citrate and peppermint oil)
ase Read code ever recorded (Relevant Read Code recorded)
≥4 antimigraine prescriptions in last year (BNF 040704%,
POM only exclude migraleve)
≥4 prescriptions in last year BNF 0103% excluding antacids
AND not ≥4 NSAIDs OR ≥4 aspirin/clopidogrel
≥4 prescriptions in last year, BNF 0106%
≥4 specified analgesic prescriptions in last year (opioids/>8 mg
cocodamol/NSAIDs) OR ≥4 specified antiepileptics in the absence
of an epilepsy Read code in last year (gabapentin, pregabalin
and carbamazepine)
rescription-only medicine.
Smith et al. BMC Medicine 2013, 11:263 Page 10 of 11
http://www.biomedcentral.com/1741-7015/11/263These data were cross-sectional, therefore no direc-
tionality or temporality can be attributed to the associ-
ation between conditions, nor can any association
confirm a causal relationship. It is possible that some
of the comorbid medical conditions assessed may have
predated or precipitated a diagnosis of bipolar disorder
(and conversely that bipolar disorder was an antecedent
for some of the medical conditions) but this is not
something that can be adequately assessed using this
cross-sectional dataset. All diagnoses were based on
administrative data, and we did not have structured in-
terviews to confirm their accuracy.
It should also be noted that an unknown (likely small)
number of patients in our bipolar group had a read code
of ‘severe/psychotic depression’. The prevalence of severe/
psychotic depression in the general population is consider-
ably lower than that of bipolar disorder and psychotic fea-
tures are present in only a minority of cases of major
depressive disorder [35]. There are also reports that indi-
cate that severe or psychotic depression may be an early
manifestation of bipolar disorder [36]. Unfortunately, due
to limitations in the way these data were extracted it was
not possible to separate out patients with psychotic de-
pression from the bipolar group, although we expect that
the proportion of patients in this sample with psychotic
depression would have been very low, given that 11 out of
the 13 Read Codes were for bipolar disorder diagnoses.
Conclusions
In the UK, the NHS provides a free at the point of access
healthcare system. Individuals should, in principle, have
equal access to physical and psychiatric healthcare. The
fundamental question that our study raises is whether this
equal access translates into equal treatment and care for
those with bipolar disorder [17].
Our results indicate that people with bipolar disorder
have high rates of multiple comorbid physical health
problems alongside underdiagnosis and/or under-recording
of cardiovascular illnesses. Although rates of ever smoking
were the same or similar in people with CHD and hyper-
tension, people with these conditions and bipolar disorder
were much more likely to be current smokers, which may
indicate that health service smoking cessation services
are insufficiently tailored to support this population.
Furthermore, individuals with bipolar disorder with a
recorded diagnosis of coronary heart disease or hyperten-
sion were less likely to be treated than those without mental
illness and may be treated less intensively. This systematic
under-recognition and undertreatment of cardiovascular
disease may contribute to substantial premature mortality
for individuals with a bipolar diagnosis in the UK.
It is well documented that physical and mental health
problems interact to cause prolonged hospitalisation,
treatment failure, poor quality of life and prematuremortality [25,37,38]. The current separation between
specialist physical and mental health services, and between
primary and secondary care services in the UK and other
countries, makes the coordinated care of the physical health
of patients with bipolar disorder difficult. Several re-
cent reports have highlighted that more integrated ser-
vices are needed but how best to achieve this is unclear
[39-41]. A thorough and detailed longitudinal analysis
of possible reasons for this health inequality, alongside
a multidisciplinary focus on improving physical health
investigation, diagnosis, treatment and monitoring for
those with bipolar disorder is needed.
Appendix I
Table 5 contains details on how each of the 32 physical
health conditions were defined from the primary healthcare
records. In most cases these were based on Read codes and
prescribing information.
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